In the news

September 10, 2008 — Xel Pharmaceuticals, Inc. announced today the completion of its prototype once-a-week Huperzine A transdermal patch for the treatment of Alzheimer's disease, and is seeking a co-development partner to bring it into the next stage. Huperzine A is a potent, highly selective and reversible inhibitor of AChE having clinically proven efficacy in oral dosage form... Read more »

July 30, 2008 — An experimental Alzheimer's drug by Wyeth and Elan was linked with a build-up of fluid in the brain called vasogenic edema. The detailed findings linked use of the drug to a wide range of potential side effects, including brain swelling, paranoia, anxiety, vomiting and high blood pressure... Read more @ Reuters »

June 30, 2008 -- Myriad Genetics, Inc. announces U.S. Phase 3 trial of Flurizan in Alzheimer's Disease fails to achieve significance on either co-primary endpoint, and has decided to discontinue its development of Flurizan. Company also indicates that similar drugs are facing high risk to fail such as AAB – 001 from Elan/Wyeth, and LV 450139 from Eli Lilly... Read more @ Reuters »

January 8, 2007 — Dr. Paul Aisen, one of nation's leading doctor for Alzheimer's disease therapy was most intrigued by evidence that Huperzine A not only improves memory as Aricept and other existing drugs without GI problems associated with old drugs, but also protects brain cells from the ravages of plaque and tangles, which the other drugs can't do... Read more @ US News »

December 3, 2006 — No one is truly happy with the current crop of drugs approved in US for Alzheimer's disease treatment, however, a compound called Huperzine A seems to combine the memory-saving effects of drugs like Aricept and Namenda with an ability to protect neurons from the beta amyloids... Read more @ Business Week »

Xel Pharmaceuticals (previously Xel Herbaceuticals), founded in 1999, has a solid and extensively experienced management and research team. Click here to see who we are.

Xel Pharmaceuticals specializes in merging advanced drug delivery technologies together with selected compounds having proven safety and efficacy from Chinese Herbal Medicine. Click here to see what we do.

Xel Pharmaceuticals' business strategy is to pursue strategic alliances with leading pharmaceutical companies to license or co-develop its proprietary technologies. Click here to see how to collaborate.